Self-Assembled Gd/Cyanine Nanoplatform for Magnetic Resonance Imaging Guided Photothermal Therapy of Thyroid Cancer
Source abstract
Abstract
Thyroid cancer, a prevalent endocrine malignancy with rising incidence, necessitates advanced strategies for precise diagnosis and effective treatment. In this study, we develop a self-assembled gadolinium-cyanine coordination-driven nanoscale metal–organic particle (CyO/Gd NPs) that seamlessly integrates magnetic resonance imaging (MRI) and photothermal therapy (PTT) for enhanced theranostic applications. The coordination-driven self-assembly endows CyO/Gd NPs with superior photostability and significantly enhanced photothermal conversion efficiency (∼50.3%) under near-infrared laser irradiation, surpassing free cyanine dyes. These nanoparticles effectively induce apoptosis and necrosis in thyroid cancer cells and exhibit potent in vivo antitumor efficacy. Furthermore, the incorporated Gd 3+ ions act as T 1 -weighted MRI contrast agents, facilitating precise tumor localization and real-time monitoring of therapeutic progress. By bridging imaging and therapy, CyO/Gd NPs offer a robust multifunctional platform for thyroid cancer theranostics, paving the way for next-generation integrated diagnostic and therapeutic nanoplatforms.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Photoacoustic and Ultrasonic Imaging · Ultrasound and Hyperthermia Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Molecular Imaging, School of Medical Technology
Qiqihar Medical University
Department of Nuclear Medicine
The First Affiliated Hospital of Qiqihar Medical University
School of Pharmacy
Department of Imaging
Department of Radiology, Children’s Hospital
Zhejiang University School of Medicine
Funding
Natural Science Foundation of Heilongjiang Province
References (32)
Show source-provided references
1. 10.1001/jama.2023.2634810.1001/jama.2023.26348 ↗
2. 10.1016/S2213-8587(21)00027-910.1016/S2213-8587(21)00027-9 ↗
3. 10.1089/thy.2020.094410.1089/thy.2020.0944 ↗
4. 10.1016/S2213-8587(22)00101-210.1016/S2213-8587(22)00101-2 ↗
5. 10.1002/hed.2659810.1002/hed.26598 ↗
6. 10.1002/ijc.3369010.1002/ijc.33690 ↗
7. 10.1634/theoncologist.2020-015910.1634/theoncologist.2020-0159 ↗
8. 10.1016/j.rcl.2020.07.00310.1016/j.rcl.2020.07.003 ↗
9. 10.1002/hed.2482510.1002/hed.24825 ↗
10. 10.7150/thno.2981710.7150/thno.29817 ↗
11. 10.1039/C8CS00234G10.1039/C8CS00234G ↗
12. 10.1016/j.ebiom.2023.10488010.1016/j.ebiom.2023.104880 ↗
13. 10.1016/j.ebiom.2023.10447610.1016/j.ebiom.2023.104476 ↗
14. 10.1002/smll.20220203510.1002/smll.202202035 ↗
15. 10.1002/smll.20210456710.1002/smll.202104567 ↗
16. 10.1016/j.colsurfb.2024.11374310.1016/j.colsurfb.2024.113743 ↗
17. 10.1186/s12951-023-02111-x10.1186/s12951-023-02111-x ↗
18. 10.1002/adhm.20210100810.1002/adhm.202101008 ↗
19. 10.2147/IJN.S38899610.2147/IJN.S388996 ↗
20. 10.1186/s12951-021-01080-310.1186/s12951-021-01080-3 ↗
21. 10.1053/j.semnuclmed.2024.01.01110.1053/j.semnuclmed.2024.01.011 ↗
22. 10.7150/thno.3494110.7150/thno.34941 ↗
23. 10.1038/s41392-023-01654-710.1038/s41392-023-01654-7 ↗
24. 10.1002/advs.20220075610.1002/advs.202200756 ↗
25. 10.1016/j.semcancer.2019.08.02210.1016/j.semcancer.2019.08.022 ↗
26. 10.1039/D4TB01822B10.1039/D4TB01822B ↗
27. 10.1016/j.jcis.2024.02.06410.1016/j.jcis.2024.02.064 ↗
28. 10.1016/j.jconrel.2019.12.04210.1016/j.jconrel.2019.12.042 ↗
29. 10.1002/advs.20230212310.1002/advs.202302123 ↗
30. 10.1021/ar200061q10.1021/ar200061q ↗
31. 10.1039/D3TB00595J10.1039/D3TB00595J ↗
32. 10.1016/j.jhazmat.2020.12422410.1016/j.jhazmat.2020.124224 ↗